News Wire

Seven public health and medical groups have filed a lawsuit challenging an FDA decision that they said would allow e-cigarettes to remain on the market for years without regulatory review, Reuters reports. The lawsuit, filed in federal court in Greenbelt, Maryland, argued the FDA in August improperly…
Despite the threat of a global health crisis in antibiotic resistance, worldwide use of antibiotics in humans soared 39% between 2000 and 2015, fueled by dramatic increases in low-income and middle-income countries (LMICs), according to a new study in the Proceedings of the National Academy of Sciences…
The FDA has approved Toujeo (insulin glargine 300 units/mL, Sanofi) Max SoloStar, the highest capacity long-acting insulin pen that will be available on the market. The new pen holds 900 units of Toujeo, more than any other long-acting insulin pen in the U.S., and provides up to 160 units/mL of Toujeo…
Aetna, Inc., has announced that it will automatically pass on drug-maker rebates to about three million commercial members at the point of sale beginning in 2019, according to a BioPharma Dive report. The move comes less than a month after UnitedHealth Group, Inc., announced a similar initiative, which…
Prices for each of the 20 most-prescribed brand-name drugs for seniors have increased dramatically every year for the past five years, according to a new report released by U.S. Senator Claire McCaskill (D- Missouri). The cost of the drugs, which include brands like Advair (fluticasone propionate and…
The FDA has approved brentuximab vedotin (Adcetris, Seattle Genetics, Inc.) in combination with chemotherapy in adult patients with previously untreated stage III or IV classical Hodgkin’s lymphoma. The approval is based on the successful outcome of the phase 3 ECHELON-1 clinical trial that compared…
The FDA has expanded the indication for nilotinib (Tasigna, Novartis) to include treatment of first- and second-line pediatric patients 1 year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). In the United States, nilotinib is now indicated…
Sun Pharma’s $80 million psoriasis licensing deal with Merck & Co. just paid off with an FDA approval, according to a FiercePharma report. But now, another challenge begins: The new med will go up against established psoriasis player Johnson & Johnson. The FDA has officially green-lighted the Indian…
The FDA has approved the ranibizumab injection (Lucentis, Genentech) 0.3-mg prefilled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy. In April 2017, Lucentis 0.3 mg became, and remains, the first and only FDA-approved medicine to treat all forms…
The second time proved to be the charm for the U.S. House of Representatives to pass right-to-try legislation that would provide terminally ill patients access to experimental drugs without the approval of the FDA, according to a BioSpace article. The House approved a second bill with a 267–149 vote…
Roche’s immunotherapy atezolizumab (Tecentriq) has racked up a third trial win in combination with other cancer drugs, a boost for the Swiss drug-maker as it seeks to muscle in on space dominated by Merck and Bristol-Myers Squibb, according to a Reuters report. A late-stage study, called IMpower131,…
GlaxoSmithKline (GSK) has a lot riding on Shingrix (zoster vaccine recombinant, adjuvanted), its new shingles vaccine. It’s one of the key products CEO Emma Walmsley cited as growth drivers for the languishing company. And that launch just got a major boost from CVS, according to FiercePharma. The…
More than nine in 10 physicians (92%) say that prior authorizations programs have a negative impact on patient clinical outcomes, according to a new physician survey released by the American Medical Association (AMA). The survey results further bolster a growing recognition across the entire health…
For the second consecutive year, total payments to care for individuals living with Alzheimer’s or other dementias are projected to surpass a quarter of a trillion dollars ($277 billion), which includes an increase of nearly $20 billion over last year, according to data reported in the Alzheimer’s…
Positive topline results have been reported from the completed phase 3 studies of the investigational agent HTX-011 (Heron Therapeutics) in patients undergoing bunionectomy (Study 301/EPOCH1) and hernia repair (Study 302/EPOCH2). HTX-011 achieved all primary and key secondary endpoints in both phase…

Pages

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA